Trials / Unknown
UnknownNCT04453488
Clinical Trial to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers
Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy of the RUTI® Vaccine to Prevent SARS-CoV-2 Infection
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 315 (estimated)
- Sponsor
- Fundació Institut Germans Trias i Pujol · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the efficacy of RUTI® vaccine preventing SARS-CoV-2 infection (COVID-19) in healthcare workers.
Detailed description
The aim of this study is to assess the efficacy of RUTI® vaccine preventing SARS-CoV-2 infection (COVID-19) in healthcare workers. The study will include a comparison between placebo and RUTI® vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | RUTI® vaccine | Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli. |
| BIOLOGICAL | Placebo | Physiological serum, 0.9% NaCl, will be used as a placebo |
Timeline
- Start date
- 2020-07-30
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
- First posted
- 2020-07-01
- Last updated
- 2020-07-29
Locations
2 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT04453488. Inclusion in this directory is not an endorsement.